Regulatory T Cells: From Nobel Prize Foundations to Engineered Tolerance and Next-Generation Immunotherapies

THE INNOVATIVE MEDICAL AND BIOLOGICAL SCIENCES JOURNAL 2026; 1(1): 1-11 REVIEW ARTICLE Regulatory T Cells: From Nobel Prize Foundations to Engineered Tolerance and Next-Generation Immunotherapies Anh Thi My Nguyen1, * 1University of Florida, Gainesville, Florida *Corresponding author’s e-mail: [email protected] Received: 1 September 2025, Revised: 27 September 2025, Accepted: 29 September 2025, Published: 15 October 2025 Highlights • Honors the 2025 Nobel Prize discoveries that established regulatory T cells (Tregs) and the transcription factor FOXP3 as the molecular foundation of immune tolerance. • Bridges foundational biology to therapy, revealing how advances in Treg heterogeneity, epigenetic stability, and tissue specialization redefine immune regulation. • Highlights next-generation immunotherapies, including CAR-Tregs and TCR-Tregs, as precision-engineered “living drugs” for autoimmunity, transplantation, and cancer. Abstract Regulatory T cells (Tregs) have emerged as central orchestrators of immune homeostasis, balancing protection against autoimmunity with the suppression of anti-tumor immunity. The 2025 Nobel Prize in Physiology or Medicine recognized Shimon Sakaguchi, Mary E. Brunkow, and Fred Ramsdell for foundational discoveries establishing Tregs as a distinct lineage of immunoregulatory cells defined by the transcription factor FOXP3. This review traces the evolution of Treg research from the discovery of CD4⁺CD25⁺ cells and the identification of the FOXP3 gene to the unification of cellular and molecular mechanisms that govern immune tolerance. We explore the phenotypic and functional diversity of Tregs, including thymus-derived and peripherally induced subsets, their epigenetic stability via the Treg-Specific Demethylated Region (TSDR), and their expanding roles beyond immune suppression, such as tissue repair and metabolic regulation. Recent advances in single-cell analysis and synthetic biology are reshaping the therapeutic landscape, enabling precise modulation of Tregs for autoimmune diseases, transplantation, and cancer. Next-generation therapies-such as CAR-Tregs and TCR-Tregs-highlight the translational potential of engineered immune tolerance, while strategies to inhibit tumor-infiltrating Tregs offer new hope for enhancing anti-tumor immunity. Together, these developments mark a new era in immunology where the manipulation of a single cell lineage may redefine both tolerance and cure. Keywords: Regulatory T cells (Tregs); FOXP3; immune tolerance; autoimmunity; cancer immunotherapy; CAR-Treg; TCR-Treg; epigenetic regulation; Nobel Prize 2025; translational immunology; cell-based therapy; immune regulation. Introduction The 2025 Nobel Prize in Physiology or Medicine recognized Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their groundbreaking discoveries elucidating the mechanisms of peripheral immune tolerance-the process by which the immune system avoids attacking the body’s own tissues [1]. Through independent but ultimately convergent lines of investigation, their collective work revolutionized immunology by revealing how the immune system maintains equilibrium between defense and restraint [1]. During the mid-1990s, immunology was dominated by the paradigm of central tolerance, which held that selfreactive T cells were eliminated in the thymus [2]. Challenging this long-standing belief, Shimon Sakaguchi proposed that an additional, active tolerance mechanism operates in the periphery [2]. His seminal experiments using neonatally IMEDBI. 2026; 1(1): 1-22 2 of 11 thymectomized mice demonstrated the existence of a circulating population of T cells capable of preventing autoimmune disease [2] (Figure 1). In his landmark 1995 publication in The Journal of Immunology, Sakaguchi identified these cells as CD4⁺ T lymphocytes expressing the α-chain of the interleukin-2 receptor (CD25) [2]. He further showed that selective depletion of this CD4⁺CD25⁺ subset led to spontaneous, multi-organ autoimmunity, whereas adoptive transfer of the same cells restored immune homeostasis. These results provided the first functional evidence of a distinct immunosuppressive cell lineage-later termed regulatory T cells (Tregs) [2]. Although initially met with skepticism, Sakaguchi’s findings established the foundation for a new field centered on active immune regulation rather than passive tolerance. While Sakaguchi was uncovering functional mechanisms of tolerance, Mary Brunkow and Fred Ramsdell approached the problem from a genetic perspective. In 2001, their research into the lethal lymphoproliferative disorder observed in scurfy mice identified mutations in a previously uncharacterized gene encoding a forkhead/winged-helix transcription factor, later named FOXP3 [3]. Crucially, analogous mutations in the human homolog of FOXP3 were found to underlie IPEX syndrome (Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked), a severe autoimmune disorder [3]. This discovery established an undeniable genetic link between a single transcriptional regulator and the maintenance of immune tolerance in both mice and humans. At the time, however, the connection between the Foxp3 gene and Sakaguchi’s suppressor T cells remained unknown. Around 2003, the final connection was made when Sakaguchi and other investigators demonstrated that Foxp3 is the master regulator controlling the development and suppressive function of the very same CD4⁺CD25⁺ T cells identified in 1995 [2]. Experimental ectopic expression of Foxp3 in conventional T cells was sufficient to reprogram them into cells with regulatory phenotypes and functions, establishing Foxp3 as the lineage-defining transcription factor of Tregs.This synthesis of functional immunology and molecular genetics marked the inception of a new era in immune regulation research. It provided both a mechanistic explanation and a molecular handle for identifying, tracking, and manipulating Tregs. The impact of this convergence is evident today, with over 200 active clinical trials investigating Treg-based therapies for autoimmune diseases, cancers, and transplant tolerance (Clinicaltrial). The 2025 Nobel Prize exemplifies how transformative discoveries often arise from the intersection of disparate research approaches. It honors the synergy between Sakaguchi’s top-down strategy-defining immune function through cellular experiments-and Brunkow and Ramsdell’s bottom-up approach, which unraveled genetic causes before identifying their immunological roles. Together, their work redefined the principles of immune tolerance and laid the foundation for the therapeutic manipulation of the immune system[1] (Figure 1, Table 1). Table 1. Landmark Discoveries Defining the Treg Lineage and the Foundations of the 2025 Nobel Prize (Source: Author) Laureate Year of Key Discovery Core Finding Significance Shimon Sakaguchi[2] 1995 Identified CD4+CD25+ T cells as mediators of peripheral immune tolerance capable of preventing autoimmune disease. Established the concept of a dedicated cell lineage for active immunosuppression (Tregs). Mary E. Brunkow & Fred Ramsdell[3] 2001 Discovered the Foxp3 gene and its link to scurfy mice and human IPEX syndrome. Provided the genetic key to immune regulation, linking a single master transcription factor to autoimmune disease. Shimon Sakaguchi[4] ~2003 Demonstrated that Foxp3 is the master regulator for Treg development and function. Unified the two lines of research, validating Foxp3 as the Treg lineagedefining marker and opening the door for their manipulation. IMEDBI. 2026; 1(1): 1-22 3 of 11 Figure 1. From Nobel Foundations to Next-Generation Treg Therapies. The discovery of CD4⁺CD25⁺ regulatory T cells and the FOXP3 transcription factor-recognized by the 2025 Nobel Prize-established the molecular basis of immune tolerance. Advances in understanding Treg heterogeneity, epigenetic stability, and tissue specialization have led to engineered “living drugs” such as CAR-Tregs and TCR-Tregs for autoimmunity and transplantation, while selective Treg inhibition in tumors offers new opportunities for cancer immunotherapy. (Drawn with Canva) The Cellular and Molecular Biology of Regulatory T Cells Following the landmark discoveries that defined the regulatory T cell lineage, subsequent research rapidly expanded to characterize their cellular diversity, molecular mechanisms, and functional stability. These efforts established Tregs not as a uniform entity but as a dynamic network of specialized subsets governed by distinct transcriptional and epigenetic programs. Defining and Identifying Tregs Regulatory T cells are functionally defined by their ability to suppress the activation and proliferation of other immune cells. However, their experimental identification relies on a combination of surface and intracellular markers. The canonical phenotype of human Tregs is CD4⁺CD25⁺FOXP3⁺CD127⁻ [5]. Each element of this signature contributes to both identification and function. CD4 designates them as part of the helper T cell lineage, while CD25, the α-chain of the interleukin-2 (IL-2) receptor, is constitutively expressed at high levels and is essential for Treg survival. Through high-affinity IL-2 binding, Tregs act as an IL-2 “sink,” depriving effector T cells of this critical growth factor and thereby exerting suppressive control. In contrast, CD127-the IL-7 receptor α-chain-is characteristically expressed at low levels, as its expression inversely correlates with FOXP3 and suppressive function[6]. Finally, FOXP3 itself serves as the lineage-defining transcription factor, indispensable for Treg differentiation and maintenance [6]. IMEDBI. 2026; 1(1): 1-22 4 of 11 While this combination of markers enables reliable identification, it also presents limitations. FOXP3 expression, although necessary for Treg function, can be transiently induced in activated conventional T cells, leading to potential contamination in Treg isolation [7]. Consequently, functional assays-such as measuring suppression of responder T cell proliferation-remain the definitive means of confirming true Treg identity. This distinction between phenotype and function is particularly critical for clinical applications, where therapeutic efficacy depends on the stability and suppressive potency of isolated or engineered Tregs [7]. Major Treg Subsets The Treg compartment is not homogeneous but comprises multiple subsets defined by their site of origin and functional specialization [8]. Broadly, two major categories are recognized: thymus-derived Tregs (tTregs), also referred to as natural Tregs (nTregs), and peripherally induced Tregs (pTregs or pTregs). tTregs originate in the thymus and constitute the primary defense against autoimmunity. Their T cell receptors (TCRs) exhibit intermediate-to-high affinity for self-antigens, allowing them to recognize and suppress potentially autoreactive clones that escape central deletion[9]. As such, tTregs represent a genetically and epigenetically “hard-wired” mechanism for maintaining self-tolerance across peripheral tissues. In contrast, pTregs arise from naïve CD4⁺ T cells in peripheral sites such as the intestinal mucosa. Their differentiation is induced by foreign antigens encountered in a tolerogenic cytokine milieu rich in TGF-β and IL-2 [10]. pTregs function primarily to establish and preserve tolerance to non-self antigens, particularly those derived from the commensal microbiota, food antigens, or environmental exposures [10]. In this way, they extend immune tolerance from intrinsic self-components to benign external stimuli, forming part of the adaptive regulatory network of the immune system. The distinction between tTregs and pTregs represents more than an academic classification; it embodies a fundamental division of labor in immune tolerance-tTregs enforce internal self-restraint, while pTregs mediate peripheral adaptation to the external environment (Table 2). This duality carries profound therapeutic implications: augmenting tTregs may be critical for treating autoimmune diseases driven by self-reactivity, whereas enhancing pTreg induction could ameliorate inflammatory disorders such as inflammatory bowel disease, which result from dysregulated responses to commensal organisms [10]. Beyond these canonical subsets, further functional diversity exists within the Treg population. Specialized subsets such as Tr1 cells, characterized by IL-10 production, and Th3 cells, defined by TGF-β secretion, contribute additional layers of immunoregulatory control[10]. Together, these populations constitute a flexible and multi-tiered network that maintains immune equilibrium across diverse physiological and pathological contexts. Table 2. Comparative Characteristics of tTregs and pTregs (Source: Author) Feature tTregs pTregs Site of Origin Thymus Peripheral lymphoid organs/tissues Primary Induction Signal High-affinity self-antigen recognition in the thymus Foreign antigen + cytokines (e.g., TGF-, IL-2) TCR Repertoire Bias Towards self-antigens Towards foreign antigens (e.g., microbial, food) Lineage Stability Highly stable, reinforced by epigenetic marks Can be more plastic, contextdependent Primary Physiological Role Maintain central and peripheral tolerance to self-antigens Maintain tolerance to harmless foreign antigens (e.g., mucosal) FOXP3 – The Master Regulator of Treg Lineage and Function IMEDBI. 2026; 1(1): 1-22 5 of 11 The discovery of FOXP3 as the master transcription factor of regulatory T cells provided a molecular foundation for understanding how Treg identity is established, maintained, and functionally stabilized. Far from being a mere phenotypic marker, FOXP3 operates as the architect of the Treg transcriptional network, orchestrating a complex gene program that enforces immune tolerance and suppressive capacity [11]. FOXP3 as a Transcriptional Hub FOXP3 functions as a dual regulator, simultaneously activating genes responsible for immunosuppression and repressing those associated with inflammatory effector programs. It promotes the expression of key suppressive molecules such as CTLA4 (cytotoxic T-lymphocyte–associated antigen 4), IL2RA (CD25), and IKZF2 (Helios), while repressing pro-inflammatory cytokine genes including IL2 and IFNG [12]. Through this balanced transcriptional control, FOXP3 defines the molecular phenotype that distinguishes Tregs from conventional CD4⁺ T cells. However, FOXP3’s activity extends beyond a simple on–off switch. Recent studies reveal that FOXP3 operates as a transcriptional cofactor or hub, whose chromatin-binding specificity and regulatory potential are shaped by partner proteins such as NFAT (nuclear factor of activated T cells), RUNX1, and GATA3. These protein interactions enable FOXP3 to integrate environmental and signaling cues-such as antigen stimulation through the TCR-to dynamically finetune its regulatory output. Depending on the interacting partners, FOXP3 can differentially suppress Th1, Th2, or Th17 responses, demonstrating a remarkable degree of functional adaptability[12]. This flexible transcriptional architecture underpins the context-dependent versatility that characterizes Treg function in diverse tissues and disease settings. The Epigenetic Scaffolding of Treg Stability While FOXP3 expression is indispensable for Treg development, its presence alone does not guarantee lineage stability. Long-term maintenance of the Treg phenotype requires a distinct epigenetic landscape that reinforces the transcriptional program and prevents reversion to effector states [12]. Without this molecular “memory,” Tregs may lose suppressive identity and convert into pathogenic, pro-inflammatory cells. One of the most critical epigenetic determinants is the Treg-Specific Demethylated Region (TSDR), a conserved non-coding element within the FOXP3 locus [13]. This region remains completely demethylated in stable Tregs-both thymus-derived and peripherally induced-but is methylated in conventional T cells, even those that transiently express FOXP3. Demethylation of the TSDR thus represents the gold-standard molecular hallmark of Treg lineage commitment and is essential for sustained FOXP3 transcription. The balance between DNA methyltransferases (DNMTs), which add methyl groups, and TET enzymes, which remove them, dynamically regulates this process [13]. In parallel, histone modifications at the FOXP3 locus also contribute to lineage integrity. Active chromatin marks, such as H3K9 and H3K27 acetylation, promote FOXP3 transcription, while repressive marks like H3K27 methylation are associated with gene silencing. The equilibrium between histone acetyltransferases (HATs) and histone deacetylases (HDACs) determines the accessibility of the FOXP3 locus. Pharmacological HDAC inhibitors have been investigated as potential tools to enhance Treg stability by promoting a more open chromatin configuration that favors FOXP3 expression[13]. Taken together, Treg lineage stability is maintained through an interdependent transcriptional–epigenetic network, in which FOXP3 expression is both a driver and a beneficiary of the underlying chromatin state. For therapeutic applications, this insight underscores a critical principle: generating stable and effective Tregs requires not only induction of FOXP3 expression but also the establishment of the correct epigenetic signature. Without this dual reinforcement, adoptively transferred Tregs may lose stability or convert into inflammatory “ex-Tregs” within a diseased environment. Thus, ensuring epigenetic fidelity is a key challenge in the clinical translation of Treg-based therapies. The Spectrum of Treg Identity Advances in single-cell and functional genomics have revealed that Tregs represent not a uniform population but a highly heterogeneous and plastic network of cells with context-dependent specialization. Beyond the classical division between thymus-derived and peripherally induced subsets, Tregs display extensive tissue-specific adaptation and functional diversity, which together expand their biological roles well beyond immune suppression [14]. Tissue-Resident Tregs IMEDBI. 2026; 1(1): 1-22 6 of 11 Tregs residing in non-lymphoid tissues (NLTs) are now recognized as distinct populations with unique phenotypic and transcriptional profiles tailored to their local microenvironments [14]. Their specialization is driven by environmental cues such as cytokines (e.g., IL-33), metabolites, and interactions with stromal and parenchymal cells. In this context, Tregs have emerged as broad regulators of tissue homeostasis, contributing to metabolic regulation, repair, and regeneration, in addition to immunosuppression. For instance, visceral adipose tissue (VAT) Tregs express the transcription factor PPAR-γ and the IL-33 receptor ST2, enabling them to maintain insulin sensitivity and prevent chronic inflammation-thereby linking immune tolerance with metabolic health. In skeletal muscle and skin, tissue-resident Tregs promote regeneration by secreting amphiregulin (Areg), a growth factor-like molecule that facilitates tissue repair [14]. In the gut, RORγt⁺ pTregs are specialized to tolerate commensal microbiota, their differentiation shaped by microbial metabolites such as short-chain fatty acids. Collectively, these examples underscore how Tregs have evolved into multifunctional guardians of tissue integrity, integrating immunologic and physiological signals[14]. Plasticity: The Double-Edged Sword of Adaptability The capacity for phenotypic plasticity enables Tregs to tailor their suppressive mechanisms to specific inflammatory contexts. Under certain stimuli, Tregs can transiently upregulate transcription factors characteristic of effector lineages-such as T-bet for Th1 or RORγt for Th17 cells-to more effectively counteract those immune responses [15]. This adaptive flexibility represents an evolutionary advantage, allowing Tregs to maintain control across diverse immunopathological conditions. However, plasticity also carries inherent risks. In chronically inflamed or cytokine-rich environments, Tregs may lose FOXP3 expression entirely, converting into pathogenic “ex-Tregs” that contribute to disease rather than suppress it (34). This instability poses significant challenges for adoptive Treg therapy, where the therapeutic goal depends on maintaining stable, suppressive phenotypes over time [15]. Understanding and controlling the molecular thresholds that distinguish beneficial adaptability from deleterious instability remains a critical focus of current Treg research [15]. Therapeutic Modulation of Tregs The therapeutic manipulation of regulatory T cells has emerged as one of the most promising yet conceptually complex areas in translational immunology. Central to this field is the principle of contextual precision-that is, understanding and modulating Treg activity in a way that is appropriate to the immunological environment. In autoimmune diseases and transplantation, the therapeutic aim is to enhance or restore Treg function to re-establish immune tolerance within a pro-inflammatory milieu. Conversely, in cancer, where excessive Treg activity suppresses anti-tumor immunity, the goal is to inhibit or deplete these cells within the tumor microenvironment (TME) while preserving their protective role elsewhere. Success in both contexts requires technologies capable of sensing, interpreting, and responding to these microenvironmental signals with high specificity and fidelity. Enhancing Treg Function for Autoimmunity and Transplantation The potential of Treg-based immunotherapy was first realized in the context of autoimmune diseases and organ transplantation, where immune tolerance is disrupted. Strategies in this domain primarily aim to reinforce the suppressive arm of the immune system, either through adoptive transfer of ex vivo expanded Tregs or through the generation of engineered, antigen-specific variants with superior precision and stability [16]. Adoptive Cell Therapy with Polyclonal Tregs One of the earliest clinical approaches involved isolating autologous Tregs from a patient’s peripheral blood, expanding them ex vivo, and reinfusing them at therapeutic doses. This polyclonal Treg adoptive cell therapy demonstrated an excellent safety profile in early-phase clinical trials and provided proof-of-concept for Treg-based tolerance induction [16]. However, its non-antigen-specific nature limits efficacy: large cell numbers are required to achieve therapeutic benefit, and off-target suppression of unrelated immune responses can occur. Furthermore, the infused Tregs must retain stability and functional integrity within inflammatory microenvironments, which often threaten to erode FOXP3 expression and lineage fidelity. Next-Generation Strategies: Antigen-Specific Treg Therapy IMEDBI. 2026; 1(1): 1-22 7 of 11 To address these limitations, the field is shifting toward antigen-specific Treg engineering, in which Tregs are genetically modified to recognize particular antigens associated with autoimmune pathology or graft rejection. This evolution mirrors the trajectory of conventional T-cell immunotherapy, now adapted for immune tolerance rather than cytotoxicity. Two principal modalities have emerged: CAR-Tregs (Chimeric Antigen Receptor Tregs): These are engineered with synthetic CARs that recognize cell surface antigens independent of MHC presentation. Upon antigen engagement, CAR-Tregs localize their suppressive activity specifically to the diseased tissue or transplanted graft, thereby achieving targeted immunomodulation with reduced systemic effects [17]. This approach holds particular promise in solid organ transplantation and inflammatory tissue disorders, where localized control is essential. TCR-Tregs (T Cell Receptor–Engineered Tregs): Unlike CAR-Tregs, these cells are equipped with defined TCRs that recognize peptide–MHC complexes derived from disease-relevant autoantigens [16]. This design confers exquisite specificity for immune regulation at the precise site of antigen presentation-an advantage for treating diseases with known autoantigenic drivers such as type 1 diabetes or multiple sclerosis. Both CAR-Tregs and TCR-Tregs exemplify the transition from broad immunosuppression to precision immune therapy, offering the potential for localized, antigen-driven tolerance induction while minimizing systemic immunocompromise (Table 3). Challenges in Treg Enhancement Despite encouraging progress, several major obstacles must be overcome before Treg-based therapies can achieve widespread clinical translation. Manufacturing remains a formidable challenge-producing sufficient numbers of stable, functionally competent Tregs at clinical scale requires standardized expansion protocols, rigorous phenotypic validation, and consistent maintenance of FOXP3 expression [18]. Another key hurdle is ensuring in vivo persistence and trafficking to target tissues. Tregs must home effectively to inflamed or grafted sites while avoiding off-target accumulation. The most critical challenge, however, lies in maintaining lineage stability. Within inflammatory or cytokine-rich environments, Tregs are vulnerable to losing their FOXP3-driven regulatory program, potentially converting into pathogenic “ex-Tregs” that exacerbate disease rather than ameliorate it [18]. Thus, while Treg enhancement strategies hold immense therapeutic potential, their success depends on mastering the balance between potency, stability, and safety-ensuring that engineered or expanded Tregs function precisely where they are needed without disrupting immune equilibrium elsewhere. Table 3. Comparative Overview of Treg – Based Immunotherapy (Source: Author) Therapeutic Strategy Mechanism of Action Specificity Key Advantage Key Challenge Polyclonal Treg Infusion Systemic, antigennon-specific immunosuppressio n. Low Relatively simple to manufacture; established safety. Requires large cell numbers; potentially limited efficacy; risk of off-target immunosuppressio n. CAR-Treg Therapy Recognizes cell surface antigen via CAR, MHCindependent. High (for surface antigen) Localized action at disease site; potentially higher potency. Requires identification of a suitable surface antigen; manufacturing IMEDBI. 2026; 1(1): 1-22 8 of 11 complexity; stability risks. TCR-Treg Therapy Recognizes MHCpresented peptide antigen via TCR. Very High (for peptide-MHC complex) Precise targeting of disease-relevant antigen-presenting cells. Restricted by patient MHC type; difficult to identify disease-relevant TCR-peptide pairs. Inhibiting Treg Function for Cancer Immunotherapy While enhancing regulatory T cell function offers therapeutic benefit in autoimmune and inflammatory diseases, in the setting of cancer, the same cells become formidable allies of the tumor. Tumor-infiltrating regulatory T cells (TITregs) actively suppress anti-tumor immune responses, creating an immunosuppressive tumor microenvironment (TME) that enables cancer cells to evade immune surveillance and resist therapies such as immune checkpoint blockade [18]. Elevated frequencies of TI-Tregs within tumors have been consistently associated with poor clinical prognosis and reduced responsiveness to immunotherapy [19]. Thus, selective inhibition or depletion of these Tregs represents a key strategy to enhance the efficacy of cancer immunotherapy. Strategies for Targeting Tumor-Infiltrating Tregs The therapeutic objective in oncology is to selectively neutralize or eliminate TI-Tregs within the tumor microenvironment while preserving systemic Treg-mediated tolerance, thereby avoiding the induction of autoimmunity. Several complementary approaches have been developed to achieve this balance: Targeting Treg-Enriched Surface Markers: Many strategies employ monoclonal antibodies against molecules that are preferentially expressed on activated Tregs within tumors, including CTLA-4, GITR, OX40, and CD25 [18]. For example, anti-CTLA-4 antibodies not only reinvigorate effector T cells but may also deplete intratumoral Tregs through Fc-mediated cytotoxicity. Similarly, targeting GITR and OX40 can both attenuate Treg suppressive function and enhance effector T cell activation. Blocking Treg Trafficking to the Tumor: Treg accumulation within tumors depends on chemokine-driven recruitment. CCR4 and CCR8, chemokine receptors highly expressed on TI-Tregs, mediate their migration into the TME [18]. Among these, CCR8 has emerged as an especially promising target, as its expression appears largely restricted to intratumoral Tregs rather than systemic populations, offering a unique therapeutic window for selective depletion with minimal collateral damage to systemic tolerance. Functional Reprogramming: Instead of depleting Tregs, newer strategies aim to reprogram their metabolic or epigenetic state to transiently impair their suppressive activity [18]. By disrupting key signaling pathways-such as lipid metabolism, oxidative phosphorylation, or chromatin remodeling-TI-Tregs can be rendered less suppressive within tumors without being eliminated entirely, thereby mitigating the risk of systemic autoimmunity. Collectively, these approaches illustrate a central paradigm shift in cancer immunotherapy: the goal is not to abolish Treg biology but to spatially and functionally constrain it, ensuring that tolerance mechanisms are silenced within tumors while preserved elsewhere. The Challenge of Specificity The greatest obstacle in targeting TI-Tregs lies in achieving cellular and molecular specificity. Many of the markers exploited for Treg depletion, including CD25 and CTLA-4, are also expressed on effector T cells essential for tumor clearance, as well as on systemic Tregs that maintain immune homeostasis [20]. As a result, broad targeting can inadvertently trigger widespread immune activation, leading to autoimmune pathology or severe immune-related adverse events. The quest for selective intervention-distinguishing malignant context–associated Tregs from physiological onesremains one of the field’s most pressing challenges. Enabling Technologies and Future Directions IMEDBI. 2026; 1(1): 1-22 9 of 11 The future of Treg research and therapeutic design lies at the intersection of systems immunology, synthetic biology, and epigenetic engineering. Rather than merely observing Treg diversity, the field is now transitioning toward the rational design of “living drugs”-cells with programmable suppressive functions, tissue-homing capabilities, and builtin safety mechanisms. High-Resolution Mapping of Treg Diversity Breakthroughs in single-cell technologies have been pivotal in redefining our understanding of Treg heterogeneity. Single-cell RNA sequencing (scRNA-seq) has revealed a continuous spectrum of Treg activation and differentiation states across tissues and disease contexts, surpassing the limitations of classical subset classification [21]. Furthermore, novel functional profiling platforms such as scSPOT (single-cell suppressive profiling of regulatory T cells) now enable simultaneous quantification of the suppressive effects of individual Tregs on diverse immune targets [22]. Together, these technologies provide an unprecedented, systems-level perspective on Treg diversity, plasticity, and function within tumors-insights that are guiding the development of next-generation therapeutic strategies. The Path Forward: Overcoming Key Hurdles Translating Treg-based therapies-whether for enhancement or inhibition-into robust clinical applications depends on overcoming several persistent challenges: Manufacturing and Scalability: Producing clinical-grade Tregs remains a significant bottleneck. Achieving reproducible, large-scale expansion of stable and functional Tregs at reasonable cost is particularly challenging for autologous therapies [23]. As previously discussed, Tregs must maintain stable FOXP3 expression and suppressive function in inflammatory microenvironments. Loss of stability can lead to the emergence of pro-inflammatory ex-Tregs, which may exacerbate disease. Approaches involving epigenetic modulators or genetic “locking” of the FOXP3 program are under investigation to address this concern [18]. The future of Treg modulation lies in achieving spatial and temporal precisiondelivering the right type of Treg to the right tissue at the right time. This will likely involve engineered logic-gated CARTregs, capable of responding only under specific local conditions, and advanced trafficking strategies to optimize tissue homing and persistence [17]. Ultimately, the dual nature of Tregs-as both protectors and suppressors-demands an equally nuanced therapeutic approach. In cancer, the ability to disarm Tregs locally without compromising systemic tolerance may represent one of the most powerful ways to unlock durable antitumor immunity. Conclusion From the foundational discoveries recognized by the 2025 Nobel Prize in Physiology or Medicine, honoring Shimon Sakaguchi, Mary E. Brunkow, and Fred Ramsdell, the study of regulatory T cells (Tregs) has evolved from a once controversial idea into a cornerstone of modern immunology. This review has traced that remarkable trajectory-from the identification of FOXP3 as the lineage-defining transcription factor, to the recognition of the remarkable heterogeneity, adaptability, and tissue specialization that characterize the Treg lineage. Together, these advances have transformed Tregs from being perceived merely as passive suppressors of immunity into multifunctional orchestrators of immune equilibrium and tissue homeostasis. Today, the field stands at a transformative crossroads. On one front, Tregenhancing therapies, including antigen-specific and engineered approaches such as CAR-Tregs and TCR-Tregs, hold promise for achieving durable immune tolerance and potentially functional cures for autoimmune and transplant-related diseases. On the other, strategic inhibition of Tregs within the tumor microenvironment has emerged as a powerful tool to amplify antitumor immunity and overcome resistance to current checkpoint-based immunotherapies. Despite the remaining hurdles-most notably in cell manufacturing, in vivo stability, and therapeutic precisionthe ongoing convergence of systems biology, epigenetic engineering, and synthetic immunology is rapidly redefining what is possible. As these frontiers continue to merge, the field is poised to finally unlock the full therapeutic potential of Tregs, not only as regulators of tolerance but as programmable architects of immune balance capable of reshaping the future of medicine. Declaration of generative AI in scientific writing During the preparation of this work, the author used OpenAI’s ChatGPT (GPT-5) to assist in language refinement, organization of scientific content, and improvement of clarity and readability. After using this tool, the author